Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.56 |
| ▸ | ACACA | Q13085 | 2/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13642589 | 1.00 | ACLY (0.56) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642529 | 0.93 | ACLY (0.54) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642672 | 0.88 | ACLY (0.53) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642528 | 0.88 | ACLY (0.53) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13420288 | 0.88 | ACLY (0.70) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642569 | 0.87 | ACLY (0.52) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642303 | 0.86 | ACLY (0.59) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642421 | 0.86 | ACLY (0.59) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642382 | 0.86 | ACLY (0.59) | ACLYACACAPTPN11HSD11B1HSD11B2 | |
| SCHEMBL13642754 | 0.86 | ACLY (0.59) | ACLYACACAPTPN11HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283217-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283217-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | APP, BACE1, BACE2 | ACLY 668/4885ACACA 195/4885PTPN11 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.